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Abstract. Mechanistic target of rapamycin (mTOR) is 
a conserved serine/threonine kinase important in cell 
proliferation, growth and protein translation. Rapamycin, a 
well-known anti-cancer agent and immunosuppressant drug, 
inhibits mTOR activity in different taxa including zebrafish. 
In the present study, the effect of rapamycin exposure on the 
transcriptome of a zebrafish fibroblast cell line, ZF4, was 
investigated. Microarray analysis demonstrated that rapamycin 
treatment modulated a large set of genes with varying functions 
including protein synthesis, assembly of mitochondrial and 
proteasomal machinery, cell cycle, metabolism and oxidative 
phosphorylation in ZF4 cells. A mild however, coordinated 
reduction in the expression of proteasomal and mitochondrial 
ribosomal subunits was detected, while the expression of 
numerous ribosomal subunits increased. Meta-analysis of 
heterogeneous mouse rapamycin microarray datasets enabled 
the comparison of zebrafish and mouse pathways modulated by 
rapamycin, using Kyoto Encyclopedia of Genes and Genomes 
and Gene Ontology pathway analysis. The analyses demonstrated 
a high degree of functional conservation between zebrafish and 
mice in response to rapamycin. In addition, rapamycin treatment 
resulted in a marked dose-dependent reduction in body size and 
pigmentation in zebrafish embryos. The present study is the 
first, to the best of our knowledge, to evaluate the conservation 
of rapamycin‑modulated functional pathways between zebrafish 
and mice, in addition to the dose-dependent growth curves of 
zebrafish embryos upon rapamycin exposure.
Introduction
Rapamycin inhibits mechanistic target of rapamycin (mTOR), 
a conserved serine/threonine kinase that responds to growth 
factors, nutrients and hypoxia (1). Rapamycin binds to the 
kinase domain of mTOR upon complexing with FK506 binding 
protein 12 (FKBP12) in TOR complex 1 (TORC1) (2) or 
through the phosphorylation of rictor, a necessary component 
of TORC2 (3). As a result, rapamycin inhibits growth in various 
cell types and thus is a promising anti-cancer agent (4).
The effect of rapamycin on mTOR function is highly 
conserved between species from yeast to humans (5,6). In 
addition, microarray analyses testing the extent of global 
alterations in the transcriptome in yeast and in mammals 
contribute to the understanding of the mechanisms and 
pathways associated with the effect of rapamycin (7-12). In vivo 
studies indicate that rapamycin results in developmental delay 
in different organisms including Drosophila melanogaster, 
zebrafish and mice (6,13,14). Previous studies using 
zebrafish have identified significant effects of rapamycin 
on autophagy (15), prevention of hepatic steatosis (16), 
heart development (17) and demonstrated the importance 
of zebrafish as a mitochondrial and ribosomal disease 
model (18,19). Although the zebrafish is an emerging model in 
drug-screening and in vivo disease models (20), evolutionarily 
conserved effects of rapamycin on the zebrafish transcriptome 
in addition to the dose-dependency in embryonic/larval size 
and pigmentation have not previously been studied.
In the present study, the transcriptional response of 
zebrafish embryonic fibroblast cell line, ZF4, was characterized 
following exposure to 100 nM rapamycin treatment for 48 h. 
To the best of our knowledge, the current study is the first 
transcriptome analysis of zebrafish ZF4 cells in response to 
rapamycin treatment demonstrating significant alterations in 
the steady state mRNA levels of zebrafish cells. In addition, 
the present study confirmed the microarray results by 
reverse transcription-quantitative polymerase chain reaction 
(RT-qPCR) for a set of genes exhibiting large effect sizes. 
Significantly altered pathways indicated by Kyoto Encyclopedia 
of Genes and Genomes (KEGG) analysis included ribosomes, 
proteasomal machinery, oxidative phosphorylation and cell 
cycle. Notably, meta-analysis performed on microarray datasets 
of mouse cell lines treated with rapamycin revealed a high level 
of conservation between the mouse and zebrafish pathways 
modulated by rapamycin. Furthermore, statistical analysis 
of shared Gene Ontology (GO) terms between zebrafish and 
mice revealed a significant positive association. Additionally, 
the present study indicated that in vivo treatment of rapamycin 
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resulted in a significant dose‑dependent reduction in body size 
and in particular, pigmentation of zebrafish.
Materials and methods
Cell culture and rapamycin exposure. ZF4, a cell line derived 
from zebrafish embryonic fibroblast cells [CRL‑2050 American 
Type Culture Collection (ATCC), Manassas, VA, USA], were 
cultured in Dulbecco's modified Eagle's medium/F-12 (1:1) 
(SH30023; GE Healthcare Life Sciences, Logan, UT, USA) 
containing 10% fetal bovine serum (FBS; CH30160; GE 
Healthcare Life Sciences) with 1% streptomycin/penicillin 
(10,000 U/ml Penicillin, 10,000 µg/ml Streptomycin; SV30010; 
GE Healthcare Life Sciences) at 28˚C. ZF4 cells were treated 
with rapamycin at a final concentration of 100 nM (553210; EMD 
Millipore, Billerica, MA, USA) or dimethyl sufloxide (DMSO; 
0.002%) as control and collected at indicated time points. ZF4 
cells previously were shown to be stable over multiple passages 
with no observable alterations in phenotype (21). ZF4 passage 
numbers (P) used for different analyses following purchase from 
ATCC were as follows: P16, microarray analysis; P19, reverse 
transcription-quantitative polymerase chain reaction (RT-qPCR); 
P20, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium 
bromide (MTT) assay; P21, propidium iodide (PI) analysis; P23, 
bromodeoxyuridine (BrdU) assay; and P19, cell death detection 
(CDD) analysis.
Cell viability and proliferation. ZF4 cells at a density of 2x104 
were treated with 100 nM rapamycin, DMSO or culture medium 
for 48 h in 96-well microplates prior to an MTT assay for cell 
viability (Vybrant MTT Cell Proliferation Assay kit, V-13154; 
Thermo Fisher Scientific, Inc., Waltham, MA, USA). The 
absorbance was read at 540 nm using a µQuant™ Microplate 
Spectrophotometer (Bio-Tek Instruments, Winooski, VT, USA). 
ZF4 cells at a density of 5x105 were seeded in 6-well 
plates in triplicate, and were treated with 100 nM rapamycin 
or DMSO for 48 h for cell cycle analysis using PI (50 µg/ml) 
staining (22). For each sample, 1x104 cells were analyzed using 
a BD FACScalibur cell analyzer (BD Biosciences, San Jose, CA, 
USA).
ZF4 cells at a density of 5x105 cells were seeded in 6-well plates 
with 100 nM rapamycin or DMSO for 48 h in triplicate, prior to 
the application of 30 µM BrdU for 24 h, to determine alterations 
in DNA synthesis. Subsequently, cells fixed with 70% ice cold 
ethanol were blocked with 10% FBS/phosphate-buffered saline 
(PBS) for 1 h, and incubated with monoclonal mouse anti-BrdU 
antibody (1:500 in 2% FBS in PBS; M0744; Dako, Glostrup, 
Denmark) for 1 h at room temperature, followed by goat 
anti-mouse secondary antibody conjugated to AlexaFluor 488 
(1:750 in 2% FBS; A11029; Thermo Fisher Scientific, Inc.) for 
1 h at room temperature. The cells were counterstained with 
4',6-diamidino-2-phenylindole (Roche Diagnostics, Basel, 
Switzerland) for 1 min and were analyzed in multiple fields 
using a Zeiss AX10 Imager A1 microscope (Carl Zeiss AG, 
Oberkochen, Germany).
The rate of apoptosis following rapamycin treatment was 
measured using a CDD enzyme-linked immunosorbent assay 
(ELISA)PLUS kit (Roche Diagnostics, GmbH, Mannheim, 
Germany) performed according to manufacturer's protocols 
following the treatment of 2x104 ZF4 cells with 100 nM 
rapamycin, DMSO or culture media for 48 h in 96 well plates, 
in duplicate. Absorbency was measured using an µQuant™ 
Microplate Spectrophotometer (Bio-Tek Instruments) at 405 nm 
using 490 nm as a reference.
Microarray experiment. A total of 5.5x106 ZF4 cells, cultured in 
T‑150 flasks in triplicate, were treated with rapamycin at a final 
concentration of 100 nM or DMSO for 48 h prior to collection. 
Total RNA was isolated using an SV Total RNA Isolation kit 
according to the manufacturer's instructions (Z3100, Promega 
Corporation, Madison, WI, USA). The quantity and quality of 
total RNA was assessed using an Agilent 2100 BioAnalyzer 
(Agilent Technologies, Inc., Santa Clara, CA, USA). All 
samples had RNA integrity number values greater than 8. 
Total RNA converted to cDNA was in vitro transcribed in the 
presence of biotinylated nucleotides to produce biotin-labeled 
cRNA (antisense RNA, 3' IVT Express kit; Affymetrix, Santa 
Clara, CA, USA). Fragmented cRNA (Ambion; Thermo Fisher 
Scientific, Inc.) was hybridized to an Affymetrix GeneChip 
Zebrafish (Affymetrix, Inc., Santa Clara, CA, USA) according 
to the manufacturer's instructions. Following staining with 
a streptavidin-phycoerythrin conjugate (Invitrogen; Thermo 
Fisher Scientific, Inc.), the intensity emitted by the bound 
RNA was quantified using a GeneChip scanner (GeneChip 
Scanner 3000 7G; Affymetrix, Inc.). The Affymetric CEL files 
and normalized expression data were deposited into the Gene 
Expression Omnibus (GEO) database (GSE53086; http://www.
ncbi.nlm.nih.gov/geo/).
Microarray data analysis. The Affymetrix GeneChip Zebrafish 
genome array contains ~15,600 probe sets. The quality control 
of the arrays and assessment of RNA integrity were performed 
in R software, version 2.10.1 (https://www.r-project.org) using 
affy (23) and affyPLM (24) packages. Raw microarray data 
were normalized using justRMA by Biometric Research 
Branch (BRB)-Array tools, version 4.2.1 (http://brb.nci.nih.
gov/BRB-ArrayTools/download.html). The differentially 
expressed genes (fold change based on the geometric mean of 
intensities) under the rapamycin treatment were determined 
using the class comparison function of the BRB-array tools. 
The significance threshold was set at P<0.05 for the univariate 
tests. Fisher's exact tests were then conducted with multiple test 
correction using Database for Annotation, Visualization and 
Integrated Discovery (DAVID; https://david.ncifcrf.gov/) 6.7 
analysis (25,26) to test the enrichment of the upregulated and 
downregulated probe sets indicated by KEGG and GO pathway 
analysis in zebrafish.
Meta‑analysis of mouse rapamycin exposure microarray 
datasets. The GEO database was searched for microarray 
datasets performed using the Affymetrix Mouse Genome 430 
2.0 Array in which mouse cell lines were treated with rapamycin. 
Samples that belong to a rapamycin treatment and associated 
control group were selected for further study. The CEL files 
were retrieved from three datasets (GSE21755, GSE19885 and 
GSE5332). Samples used from GSE21755 included rapamycin 
(n=2, 20 nM for 24 h) and control (n=3, DMSO for 24 h) treatments 
on two different tuberous sclerosis (Tsc) null mouse embryonic 
fibroblast lines (MEFs), Tsc1-/- (p53+/+, 3T3-immortalized) and 
Tsc2-/- (p53-/-, derived from a littermate of the wild-type cell 
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line) (11). From GSE19885, rapamycin (100 nM for 24 h; n=3) 
and control (DMSO for 24 h; n=3) treated samples from a 
rapamycin sensitive mouse brain tumor cell line, BC3H1, were 
used (12). From GSE5332, TSC2-/- MEFs treated with 20 nM 
rapamycin or DMSO for 14 h (n=6) (10) were included in the 
meta-analysis. The quality control analysis of the CEL files 
was performed using R packages affyQCReport (https://www.
bioconductor.org/packages/release/bioc/html/affyQCReport.
html) (23) and af f yPLM (https://www.bioconductor.
org/packages/release/bioc/html/affyPLM.html) (24). One 
sample (GSM497116) from GSE19885 did not pass the quality 
control check thus was excluded from further analysis. CEL 
files normalized using robust multichip average (23) were 
subjected to meta-analysis using MetaDE Bioconductor package 
(https://cran.r-project.org/web/packages/MetaDE/index.
html) (27). Normalized expression data along with control 
and treatment sample labels for each GSE dataset were given 
as input to meta-analysis function for calculation of z-scores, 
P-values and the false-discovery rate (FDR) using a random 
effects model (1,000 permutations; seed value set to 123). 
Table II. Kyoto Encyclopedia of Genes and Genomes pathway results from the Database for Annotation, Visualization and 
Integrated Discovery for upregulated and downregulated genes in zebrafish (Benjamini <0.05) and respective results from mice 
meta-analysis for rapamycin treatment.
 Zebrafish microarray Mouse meta‑analysis
 ---------------------------------------------------------------------- --------------------------------------------------------------------
Genes Count P-value Benjamini Count P-value Benjamini
Upregulated genes
  Ribosome 15 1.5x10-06 1.3x10-04 36 5.8x10-18 9.3x10-16
Downregulated genes
  Oxidative phosphorylation 42 1.9x10-15 2.3x10-13 25 4.2x10-03 3.7x10-02
  Cell cycle 32 4.9x10-08 3.0x10-06 27 6.9x10-04 7.8x10-03
  Proteasome 16 1.5x10-05 6.1x10-04 27 3.5x10-14 3.0x10-12
  Valine, leucine and isoleucine degradation 13 7.6x10-05 2.3x10-03 6 5.4x10-01 8.2x10-01
  Glutathione metabolism 11 6.2x10-04 1.5x10-02 11 4.2x10-02 1.9x10-01
  Progesterone-mediated oocyte maturation 20 7.3x10-04 1.5x10-02 9 6.9x10-01 8.9x10-01
  Arginine and proline metabolism 14 8.4x10-04 1.5x10-02 10 1.0x10-01 3.5x10-01
  Glycolysis/gluconeogenesis 14 1.2x10-03 1.8x10-02 19 1.6x10-04 2.5x10-03
  N-glycan biosynthesis 11 2.6x10-03 3.5x10-02 6 5.4x10-01 8.2x10-01
  Pyruvate metabolism 10 3.1x10-03 3.7x10-02 11 8.6x10-03 6.1x10-02
  Oocyte meiosis 21 3.9x10-03 4.2x10-02 15 3.3x10-01 6.7x10-01
  Fatty acid metabolism 9 4.5x10-03 4.5x10-02 3 9.6x10-01 9.9x10-01
  Tricarboxylic acid cycle 9 4.5x10-03 4.5x10-02 7 1.0x10-01 3.5x10-01
Benjamini, Benjamini-Hochberg corrected P-value.
 
Table I. Primers and the primer efficiencies used for the microarray confirmations.
Gene name Forward primer (5'-3') Reverse primer (5'-3') Primer efficiency
foxm1 GACACATGACCCTGAAGGAGA AGAGTGAGACAGCGGTTTGC 1.90
pah TGTGGGTATCGTGAGGACAA GGAGCTGTGGCGAATGTACT 1.75
cyp26b1 CAACACGGGACAAGAGCTG CCCATAAGAACCTTACGCACA 1.92
tagln2 GCTGGTACAGTGGATCGTCA TGGATCTTCTTCACAGGCTTT 1.98
ddc CCTGCCTGTACGGAGCTAGA CTGGATCAGCCTGACGATTT 1.85
bambia TTTGCATGACCTCACACACC CGGAACCACACCTCTTTAGC 1.91
dkk1b CGCTATTAAAGTCGGTTCAGG TTGCACTGGAGACAGACACC 1.89
wif1 CAGACTCTGCGTTCTTTGGA GGATGGTCACCTCAAATGCT 1.86
mmp9 CAAGACATTCGACGGAGACC TGCTTTCCCGAAAGAGATCA 2.00
b2m TTCTTTGTCTGCTGTACATCACTG TGCTTGGTGTCCGACATAAC 1.95
foxm1, forkhead box M1; pah, phenylalanine hydroxylase; cyp26b1, cytochrome P450, family 26, subfamily b, polypeptide 1; tagln2, trans-
gelin 2; ddc, dopa decarboxylase; bambia, BMP and activin membrane-bound inhibitor (Xenopus laevis) homolog a; dkk1b, dickkopf 1b; wif1, 
wnt inhibitory factor 1; mmp9, matrix metalloproteinase 9; b2m, beta-2-microglobulin.
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Filtered probes with FDR <0.005 (corresponding P‑value: 
5.7x10-4) were used for further DAVID analysis. Meta-analysis 
was conducted in R software, version 3.1.2. Significant KEGG 
and GO pathways were extracted using DAVID for up- and 
downregulated mouse probe sets separately and then associated 
with the zebrafish functional pathway results.
RT‑qPCR validation experiments. Results from the microarray 
data were confirmed for selected significantly upregulated or 
downregulated genes by RT-qPCR analysis. An independent 
set of rapamycin treatment experiments was performed in 
which 5x106 ZF4 cells were treated with 100 nM rapamycin or 
DMSO in triplicate for 6 or 48 h prior to collection. For each 
sample, 1.2 µg RNA, reverse transcribed into cDNA according 
to the manufacturer's instructions (K1622; Fermentas; Thermo 
Fisher Scientific, Inc.), was amplified with sequence specific 
primers designed using Primer3 (Table I; http://frodo.wi.mit.
edu/primer3/). qPCR reactions were performed using an iCycler 
(Bio-Rad Laboratories, Inc., Hercules, CA, USA) for each 
sample in duplicate, using DyNAmo HS SYBR Green qPCR 
Kit (F-410 L; Thermo Fisher Scientific, Inc.). The running 
parameters were as follows: 1 cycle at 95˚C for 10 min, followed 
by 45 cycles of 95˚C for 30 sec, 60˚C for 30 sec, 72˚C for 30 sec, 
and finally 72˚C for 10 min. b2m was used as the reference 
gene (28). The 10-fold serial dilutions were used to identify the 
primer efficiencies (E) (Table I). A modified 2-ΔΔCq method (29) 
was applied to calculate fold expression change of selected genes: 
(Etarget)ΔCtTarget (control-sample)/(Eref)ΔCtReference (control-sample). The fold 
changes values were log2 transformed prior to plotting and 
performing statistical analyses.
Rapamycin treatment of zebrafish embryos. Shield stage 
zebrafish embryos (EMBL Heidelberg, Heidelberg, Germany) 
were placed into 96-well plates; each well contained 3 embryos. 
Final concentrations of 2, 10 and 20 µM rapamycin (R0395; 
Sigma-Aldrich, St. Louis, MO, USA) or equivalent DMSO 
concentrations were added to the embryo medium. Zebrafish 
embryos were collected at 1-5 days post fertilization (dpf) for 
further examination. The study was approved by the Bilkent 
University Local Animal Ethics Committee (No. 2003/5; Bilkent 
University, Ankara, Turkey); and in vivo zebrafish rapamycin 
exposure experiments were performed at European Molecular 
Biology Laboratory (Heidelberg, Germany) in compliance with 
local animal care regulations.
Statistical analysis. Minitab software, version 13.20 
(Minitab Inc., State College, PA, USA) was used to analyze 
the significance of the RT‑qPCR, MTT, BrdU, CDD and PI 
staining and in vivo results. The significance between groups 
was detected with Fisher's pairwise comparisons following a 
one-way analysis of variance (ANOVA). RT-qPCR results from 
6 and 48 h rapamycin or equivalent of DMSO treatments were 
analyzed with either one-way or two-way ANOVA as necessary. 
A general linear model was applied to detect the significance of 
dose- and time-dependent rapamycin treatment on body length 
in vivo in zebrafish embryos. The graphs were generated using 
GraphPad Prism software, version 5.0 (GraphPad Software, 
Inc., San Diego, CA, USA). P<0.05 was considered to indicate 
a statistically significant difference. The Pearson correlation 
coefficient and associated P‑value were calculated using the 
cor.test function in R. Functional analyses were performed 
using DAVID version 6.7. For DAVID based pathways and 
GO analyses, P-values corrected using the Benjamini Hochberg 
method were reported; Benjamini<0.05 was considered 
to indicate a statistically significant difference. Zebrafish 
and mouse GO term lists [biological process (BP); cellular 
compartment (CC); molecular function (MF)] were matched 
with each other; and shared terms having P≤0.05 were tested for 
a significant positive association using odds ratios (OR, based 
on the conditioned maximum likelihood estimate) calculated 
using two-sided Fisher's exact test from the exact2x2 package in 
R software, version 3.1.2 (30,31).
Results
Rapamycin reduces basal apoptosis with no detectable 
alteration in cell viability or proliferation in ZF4 cells. The 
results indicated that 100 nM rapamycin did not have significant 
effects on cytotoxicity or DNA synthesis in ZF4 cells (one-way 
ANOVA; MTT, P=0.47; BrdU, P=0.141; data not shown). In 
addition, cell fractions in G0/G1, S and G2/M phases or in 
subG1 phase did not differ between the rapamycin and DMSO 
treated groups (one-way ANOVA for subG1 phase; P=0.394; 
data not shown). Notably, however, the ELISA-based CDD 
analysis showed that rapamycin significantly reduced the basal 
apoptosis in ZF4 cells (one-way ANOVA; P=0.01; Fig. 1).
Rapamycin af fects steady state mRNA expression in 
zebrafish ZF4 cells. The differentially expressed genes 
between rapamycin and DMSO control groups were obtained 
using the class comparison function of the BRB array tools 
(P<0.05). This model is preferable for data with small 
number of samples since it uses a random variance model 
for univariate tests to compute a P-value for each probe set 
together with an FDR value (32). A total of 2,186 probe sets 
Table III. Counts for the significant (P<0.05) shared GO terms 




 All shared terms terms removed
 --------------------------------- ---------------------------------
Zebrafish Down Up Down Up
GO-BP
  Down 54 13 43 2
  Up 3 18 1 16
GO-CC
  Down 23 8 17 3
  Up 12 8 3 0
GO-MF
  Down 18 2 17 1
  Up 5 6 4 5
GO, gene ontology; BP, biological process; CC, cellular component; 
MF, molecular function.
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(904 upregulated and 1,282 downregulated) were detected as 
significantly modulated between the rapamycin and DMSO 
groups at P<0.05.
RT‑qPCR validation and microarray results are correlated. 
To validate the microarray results, RT-qPCR was used 
to test whether rapamycin treated ZF4 cells exhibited 
time-dependent alterations in gene expression (at 6 and 48 h). A 
total of nine genes (seven upregulated and two downregulated) 
were selected that exhibited high fold-change differences, low 
P-values and FDRs. Of the nine selected genes, six showed 
statistically significant alterations in time or treatment or both 
(P<0.05; Fig. 2). These genes included dopa decarboxylase 
(ddc), cytochrome P450, family 26, subfamily b, polypeptide 1 
(cyp26b1), dickkopf 1b (dkk1b), wnt inhibitory factor 1 (wif1), 
forkhead box M1 ( foxm1) and phenylalanine hydroxylase (pah) 
(Fig. 2). Overall, the log2 fold changes of all the selected genes 
at 48 h of rapamycin exposure were highly correlated between 
the microarray and RT-qPCR data (Pearson correlation 
coefficient, r=0.79, P=0.011; Fig. 3).
KEGG pathway and GO enrichment analyses reveal high 
conservation between zebrafish and mouse in the response to 
rapamycin. According to KEGG pathway analysis in zebrafish, 
genes coordinately upregulated in response to rapamycin 
treatment were largely the components of small and large 
nuclear ribosomes, while those that were downregulated were 
enriched for proteasomal complexes, oxidative phosphorylation, 
the cell cycle, glycolysis/gluconeogenesis and certain metabolic 
pathways (Table II). Meta-analysis of the mouse datasets 
identified 5,019 consistently however, differentially expressed 
probe sets (FDR <0.005) among which 2,776 were downregulated 
and 2,243 were upregulated. KEGG pathway comparisons 
between zebrafish and mice revealed that ribosome was the 
most significantly upregulated pathway term, while several 
pathways downregulated in zebrafish were also downregulated 
in mice (Table II). Similarly, the shared GO terms between 
the zebrafish and mouse rapamycin datasets were identified 
(Table III). Commonly upregulated GO terms for CC included 
ribosomal and ribonucleoprotein complexes, while proteasome 
complexes, endoplasmic reticulum and mitochondrion terms 
were among the commonly downregulated CC terms (data not 
shown). However, Fisher's exact test for GO-CC did not indicate 
a significant positive association for the significant (P≤0.05) 
shared terms from mouse and zebrafish [OR, 1.89; (95% CI, 
0.53-6.52); P=0.36; Table III]. Conversely, for GO terms of MF, 
an overall significant positive association was found between 
zebrafish and mice (OR, 9.79; (95% CI, 1.58‑86.01); P=1.2x10-2; 
Table IV. Top five shared significant (Benjamini <0.05) GO‑BP term results from Database for Annotation, Visualization and 
Integrated Discovery categories for the upregulated and downregulated genes following rapamycin treatment.
 Zebrafish microarray Mouse meta-analysis
 ---------------------------------------------------------------- -----------------------------------------------------------------
GO-BP terms Count P-value Benjamini Count P-value Benjamini
Upregulated genes
  GO:0006412; translation 25 6.9x10-05 1.1x10-02 52 1.5x10-07 6.1x10-05
  GO:0048598; embryonic morphogenesis 23 6.3x10-05 1.3x10-02 48 1.0x10-04 7.4x10-03
  GO:0048568; embryonic organ development 17 1.8x10-04 2.0x10-02 34 4.8x10-04 2.5x10-02
  GO:0009792; embryonic development ending 16 1.8x10-04 2.3x10-02 55 7.2x10-05 5.6x10-03
  in birth or egg hatching 
  GO:0043009; chordate embryonic development 16 1.8x10-04 2.3x10-02 54 1.1x10-04 7.5x10-03
Downregulated genes
  GO:0006259; DNA metabolic process 35 5.0x10-07 1.3x10-04 79 4.7x10-08 4.8x10-06
  GO:0007049; cell cycle 31 3.9x10-07 1.4x10-04 96 7.1x10-06 3.8x10-04
  GO:0006091; generation of precursor metabolites 28 8.0x10-07 1.4x10-04 62 1.6x10-10 2.7x10-08
  and energy 
  GO:0005996; monosaccharide metabolic process 19 9.8x10-06 7.2x10-04 41 4.5x10-06 2.5x10-04
  GO:0019318; hexose metabolic process 18 2.0x10-05 1.2x10-03 39 1.3x10-06 8.0x10-05
GO-BP, gene ontology-biological process; Benjamini, Benjamini-Hochberg corrected P-value.
 
Figure 1. Cell death detection assay of rapamycin treated ZF4 cells. One-way 
analysis of variance with Fisher's multiple comparisons were performed to 
test the significance (*) of rapamycin treatment from the control (P=0.017) 
and DMSO (P=0.004). DMSO, dimethyl sufloxide.
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Table III). Several GO-MF categories, including DNA 
binding, structural constituent of ribosomes, threonine-type 
endopeptidase and peptidase activity, and cofactor binding, 
were common between zebrafish and mice. Similarly, shared 
zebrafish and mouse GO -BP terms were significantly and 
positively associated with each other [OR, 23.68; (95% CI, 
5.84-107.61); P=6.3x10-8; Table III]. Upregulated GO-BP terms 
primarily included embryonic processes such as embryonic 
morphogenesis and embryonic organ development, while the top 
downregulated GO-BP terms were enriched in DNA metabolic 
process and the cell cycle, as in the KEGG pathway analysis 
(Table IV).
Some of the generalized GO terms, such as translation 
and cell cycle, were significant in both up and downregulated 
categories, particularly in mice. Following the removal of 
such ambiguous (both up and downregulated) terms, the 
P‑values of the Fisher's test results for BP [OR, 253.65; (95% 
CI, 25.08-7219.69); P=9.1x10-12] and MF [OR, 18.22; (95% 
CI, 1.52-521.42); P=7.9x10-03] categories remained significant. 
However the Fisher's test for GO‑CC remained insignificant.
The Fisher's tests for GO term association between 
zebrafish and mice were repeated for different FDR values of 
mouse meta‑analysis (i.e. FDR<0.05, FDR<0.01 and the top 
ranked 2,186 probes) to test whether the observed associations 
Figure 2. Genes showing significant modulations by microarray and RT‑qPCR analyses. The significantly upregulated genes selected for RT‑qPCR confirma-
tion were (A) ddc, (B) dkk1b; (C) cyp26b1 and (D) wif1. Two-way ANOVA, ddc, Ptreatment= 0.022, Ptime ≤0.001; dkk1b, Ptreatment ≤0.001, Ptime=0.004; cyp26b1, 
Ptreatment=0.008, Ptime=0.039; wif1, Ptreatment=0.004, Ptime=0.039. The significantly downregulated genes by rapamycin in RT‑qPCR analysis were (E) pah and 
(F) foxm1. Two-way ANOVA, pah, Ptreatment ≤0.001, Ptime=0.884; foxm1, Ptreatment=0.098, Ptime=0.010. *P<0.05 DMSO vs. rapamycin; #P<0.05 6 h vs. 48 h. 
RT-qPCR, reverse transcription-quantitative polymerase chain reaction; ANOVA, analysis of variance; ddc, dopa decarboxylase; dkk1b, dickkopf 1b; 
cyp26b1, cytochrome P450, family 26, subfamily b, polypeptide 1; wif1, wnt inhibitory factor 1; pah, phenylalanine hydroxylase; foxm1, forkhead box M1; 
DMSO, dimethyl sulfoxide.
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at FDR<0.005 were robust. Fisher's tests using probe sets 
specified at each FDR cut‑off revealed that GO‑BP (all terms) 
were significantly positively associated between zebrafish 
and mice regardless of the FDR values selected (FDR<0.05, 
P=3.1x10-14; FDR<0.01, P=1.2x10-09; top 2,186 ranked probes, 
P=3.4x10-05). A similar result was observed for GO-MF 
at FDR of 0.01 (P=7.8x10-03) and top 2,186 ranked probes 
(P=3.0x10-02), however, not for FDR<0.05 (P=0.12). Consistent 
with FDR value of 0.005, the Fisher's test for GO-CC was not 
significant at any other selected value.
Effects of rapamycin on body size and pigmentation are 
dose‑dependent. Rapamycin has been shown to limit growth in 
multiple organisms, however, the dose- and time-dependency of 
such effects have not been well assessed. Therefore, the effects 
of rapamycin on the development of zebrafish embryos (TLF) 
treated with increasing doses of rapamycin were assessed 
at different time points (1-5 dpf). The results suggested that 
rapamycin resulted in a significant delay in the development of 
the embryos in a dose- and time-dependent manner, indicated 
by the alterations in body length (Fig. 4). Rapamycin treated 
embryos had larger yolks and shorter body sizes, and the effect 
of rapamycin on body size was more apparent at 10 and 20 µM 
treatments compared with the 2 µM treatment (Figs. 4 and 5). 
In particular, rapamycin treated embryos exhibited marked 
reduction in melanocyte distribution, with this observed to be 
dose-dependent (Fig. 5A and B).
Discussion
The present study, to the best of our knowledge, is the first 
characterization of the global transcriptional response of a 
zebrafish cell line (ZF4) when exposed to 100 nM rapamycin. 
Rapamycin treatment in zebrafish was demonstrated to result 
in the coordinated modulation of genes that belonged to 
pathways important in cell growth, division and metabolism. 
Meta-analysis of heterogeneous mouse microarray datasets 
then enabled the identification of functional pathways similarly 
and significantly modulated in zebrafish and mice in response 
to rapamycin (Tables II and III). Thus, the current study 
represents an important step in an improved understanding of 
the functional conservation of mTOR inhibition by rapamycin 
among vertebrates.
Comparative KEGG pathway analysis identified that 
ribosome was the most significant pathway upregulated in 
both species when exposed to rapamycin, while proteasome 
complexes, oxidative phosphorylation, the cell cycle and certain 
metabolic pathways were commonly downregulated (Table II). 
A well-known effect of rapamycin on cellular metabolism is the 
inhibition of translation through the modulation of ribosomal 
subunits and/or eukaryotic translational factors (33). In the 
yeast model, rapamycin negatively affects both the steady state 
and polysome-associated mRNA levels of genes involved in 
RNA processing and ribosome biogenesis together with the 
proteasome (9). However, in reports regarding vertebrates, 
the effects of rapamycin on ribosomes have been attributed 
predominantly to alterations in the polysome-associated 
mRNA pool (34,35). The comparative transcriptomics of the 
present study indicated that, in both zebrafish and mice, steady 
state mRNA levels of ribosomal subunits were upregulated 
coordinately. These results indicate that rapamycin may result 
in an increased accumulation of nuclear ribosomal subunit 
mRNAs in vertebrates. Although small in magnitude, this 
collective increase may actually be effectively large since 
ribosomal subunits are highly expressed.
The observed increase in nuclear ribosomal component 
expression may be the result of translation inhibition itself. With 
the stalling of translation or sequestering of mRNAs, a surplus 
of mRNA for the translational machinery may accumulate (36); 
however, this requires further investigation. Notably, a previous 
study indicated that translational inhibitors paradoxically 
induced the transcription of ribosomal architecture components 
and translational regulatory factors (37). The implications 
of an increase in the ribosomal mRNA pool in response to 
translational inhibition may be associated with the apoptotic 
and survival-associated functions of rapamycin treatment. It has 
been previously demonstrated that ribosomal subunit mRNAs 
may regulate apoptosis driven by p53, and thus have implications 
in cell survival and apoptosis (38).
Additionally, the current study demonstrated a coordinated 
but mild downregulation of a subset of the mitochondrial 
ribosomal proteins in rapamycin treated ZF4 cells and mouse cell 
lines, indicated by the significant enrichment of mitochondrion 
and mitochondrial part terms among downregulated GO-CC 
terms (data not shown, Benjamini <0.05). This result is in 
accord with previous studies reporting that rapamycin resulted 
in the downregulation of mitochondrial ribosomes (10). The 
proteasome was a significantly downregulated KEGG pathway, 
for both zebrafish and mice (Table II). Additionally, a previous 
study indicated that rapamycin was able to downregulate 
proteasome subunits at the transcriptional and translational 
levels in human E6-1 Jurkat T cells (34). Hence, by reducing 
proteasomal subunit expression, rapamycin may also act as a 
proteasomal inhibitor in zebrafish.
Figure 3. Pearson correlation plot for the microarray and RT-qPCR fold 
changes (log2) for the selected upregulated and downregulated genes. 
RT-qPCR, reverse transcription-polymerase chain reaction.
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Cellular analyses indicated that in ZF4 cells, rapamycin 
reduced the rate of basal apoptosis while having no significant 
effect on cell viability or proliferation. As previously indicated, 
rapamycin may induce or protect cells from apoptosis (39,40). 
The current study suggests that rapamycin may have a protective 
effect against apoptosis in ZF4 cells that can potentially mask 
Figure 5. Effects of rapamycin treatment on the embryonic development of zebrafish. Shield stage zebrafish embryos were treated with 2, 10 and 20 µM 
rapamycin or DMSO prior to collection at the indicated time points. (A) Rapamycin and DMSO treated embryos at 1 and 3 dpf. (B) Effect of rapamycin treat-
ment on melanophore pigmentation (arrows) at 4 dpf. Scale bars = 100 µm. DMSO, dimethyl sulfoxide; dpf, days post fertilization; Rap, rapamycin.
Figure 4. Time‑ and dose‑dependent alterations in body size following treatment with (A)  2, (B) 10 and (C) 20 µM rapamycin. The lengths of the fish were mea-
sured from the tip of the head to the end of notochord in mm, and the mean plotted against the time of development. Data are presented as the mean ± standard 
deviation. General linear model; Pdose ≤0.001, Ptime ≤0.001, Prapamycin ≤0.001. dpf, days post fertilization; DMSO, dimethyl sulfoxide; RAP, rapamycin. 
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alterations in cell number and viability. The MTT test did not 
indicate a significant growth inhibition in ZF4 cells following 
rapamycin treatment, however, rapamycin was observed to 
significantly downregulate zebrafish and mouse KEGG and 
GO-BP pathways including the cell cycle (Tables II and IV).
Notably, the correlations among the three individual mouse 
dataset fold change values (log2) were significantly high, 
ranging between 0.21 and 0.59 regardless of the mutations 
the cell lines carried (Tp53, Tsc1 and Tcs2 genes). This 
suggests that the meta-analysis used in the current study was 
able to capture a significant portion of the conserved aspects 
of rapamycin treatment in mice, which may then be extended 
to zebrafish, a non‑mammalian vertebrate. A previous study 
showed that ZF4 cells exhibited a drastic cellular growth 
inhibition and a reduction in the expression of conserved E2F1 
pathway-associated genes in response to serum starvation (41). 
Accordingly, the present study indicates that the ZF4 cell line 
is a valuable model for detecting conserved modulators of cell 
growth and division-associated genes and pathways.
Additionally, the present study provided a foundation for 
the identification and validation of novel genes affected by 
rapamycin treatment time-dependently using ZF4 fibroblast 
cells. The correlation between the log fold changes obtained from 
the independent RT-qPCR and microarray data in response to 
rapamycin was significantly high, however, it was only possible 
to confirm the significance of 55% of the genes by RT‑qPCR. 
The discrepancies between the RT-qPCR and microarray 
results may result from the differences arising from the use of 
different cell passages in the experiments and/or potentially 
different probe and primer sequences/dynamics between the 
microarray and RT-qPCR methodologies (42). Upon validation 
by RT‑qPCR, a significant modulation in response to rapamycin 
was observed in several pigmentation associated genes, with an 
increase in the expression of dkk1b and ddc and a reduction in 
pah expression (Fig. 2). In a previous study, the overexpression 
of DKK1 suppresses melanocyte growth and proliferation 
in human keratinocytes (43). DDC provides dopamine by 
conversion from dopa, which also can be used for melanin 
production, such as in butterfly wings (44). PAH supplies tyrosine 
for melanin production and contributes to melanogenesis (45), 
and PAH (Enu) mice have inactive TORC1 (46). The role of 
TOR signaling in melanin pigmentation has also been observed 
in Drosophila, such that increased TORC1 activity resulted in 
altered pigmentation (47).
Zebrafish embryos and adults have been shown to be 
sensitive to rapamycin. For instance, treatment with 400 nM 
rapamycin resulted in a mild delay in embryonic development 
while arresting digestive tract development 72 hpf following 
exposure (6). Similarly, 10 nmol/l rapamycin treatment 
phenocopied embryonic growth-associated protein morphants 
exhibiting developmental delays, vessel defects and cardiac 
failure (48). In addition, the growth of the adult caudal 
fin in zebrafish was negatively affected by treatment with 
rapamycin (49). The present in vivo study not only confirmed 
the growth limiting effects of rapamycin in zebrafish but also 
implicated a dose-dependent role for mTOR inhibition in 
pigmentation-associated processes. Indeed, a negative effect 
of rapamycin on melanocytes has been indicated in a Xenopus 
model (50), complementing the alterations observed in the 
present study regarding pigmentation upon rapamycin exposure 
in zebrafish (Fig. 5). However, the mechanisms underlying the 
effects of rapamycin on pigmentation should be explored at the 
transcript level in vivo.
In conclusion, the present study indicates that rapamycin 
modulates a wide range of transcripts in ZF4 cells, including 
nuclear and mitochondrial ribosomal machinery components 
and proteasomal subunits. These functional alterations were 
supported by KEGG and GO pathway meta-analysis of mouse 
microarray datasets of rapamycin exposure. This is the first 
report, to the best of our knowledge, of the conservation between 
the zebrafish and mouse functional pathway enrichment profiles 
in response to an mTOR inhibitor. Furthermore, the significantly 
affected genes produced high gene enrichment scores suggesting 
that a coordinated set of conserved events occurs in response 
to rapamycin in zebrafish and mice. Additionally, the results 
revealed that the response of zebrafish embryos to rapamycin 
exhibits similarities with those from other organisms, providing 
a foundation for comparative expression profiling studies of 
rapamycin treatment between zebrafish and mammals.
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